Isoprenoids and related pharmacological interventions: Potential application in Alzheimer's disease

Molecular Neurobiology

Volumn 46, Issue 1, 2012, Pages 64-77

  Li, Ling ^a   Zhang, Wei ^a   Cheng, Shaowu ^a   Cao, Dongfeng ^a   Parent, Marc ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Alzheimer's disease; Bisphosphonates; Isoprenoids; Prenyltransferase inhibitors; Protein prenylation; Statins

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ALENDRONIC ACID; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; CELL PROTEIN; DIMETHYLALLYLTRANSFERASE; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; GUANOSINE TRIPHOSPHATASE; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; ISOPRENOID; L 778123; LONAFARNIB; MEVINOLIN; PAMIDRONIC ACID; PITAVASTATIN; PRAVASTATIN; RISEDRONIC ACID; ROSUVASTATIN; SIMVASTATIN; TIPIFARNIB; ZOLEDRONIC ACID;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CARBOXY TERMINAL SEQUENCE; CELL FUNCTION; COGNITION; CYTOSKELETON; HUMAN; HYDROPHILICITY; IMMUNOMODULATION; LIPOPHILICITY; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PROTEIN PRENYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SUBUNIT;

EID: 84868146096     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-012-8253-1     Document Type: Article

References (164)

1. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425-430
2. Lane KT, Beese LS (2006) Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. J Lipid Res 47:681-699
3. McTaggart SJ (2006) Isoprenylated proteins. Cell Mol Life Sci 63:255-267 (Pubitemid 43202309)
4. 4S Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L,Warnica JW, Arnold JM,Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001-1009 (Pubitemid 26338729)
6. Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232:34-47 (Pubitemid 16037973)
7. Jones PH (2003) Comparing HMG-CoA reductase inhibitors. Clin Cardiol 26:I15-20 (Pubitemid 36070953)
8. Shitara Y, Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71-105 (Pubitemid 44301483)
9. Istvan ES, Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292:1160-1164 (Pubitemid 32440937)
10. Schachter M (2005) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117-125 (Pubitemid 40204354)
11. Yee LL, Wright EA (2011) Pitavastatin calcium: clinical review of a new antihyperlipidemic medication. Clin Ther 33:1023-1042
12. Liao JK (2002) Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110:285-288 (Pubitemid 34847957)
13. Vaughan CJ (2003) Prevention of stroke and dementia with statins: effects beyond lipid lowering. Am J Cardiol 91:23B-29B (Pubitemid 36263245)
14. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205-3210 (Pubitemid 30422037)
15. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic- Plese S, Preiningerova J, Rizzo M, Singh I (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363:1607-1608 (Pubitemid 38625664)
16. Shepardson NE, Shankar GM, Selkoe DJ (2010) Cholesterol level and statin use in Alzheimer disease: II. review of human trials and recommendations. Arch Neurol 68:1385-1392
17. Fernandez Martinez M, Castro Flores J, de Las P, Heras S, Mandaluniz Lekumberri A, Gordejuela Menocal M, Zarranz Imirizaldu JJ (2008) Risk factors for dementia in the epidemiological study of Munguialde County (Basque Country-Spain). BMC Neurol 8:39
18. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB (1995) Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: A case-control study. Neurology 45:1092-1096
19. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M,ManjonM, Girones X, Henry TL,Matsubara E, Zambon D, Wolozin B, Sano M, Cruz-Sanchez FF, Thal LJ, Petanceska SS, Refolo LM (2003)Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61:199-205 (Pubitemid 36875301)
20. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98:5856-5861 (Pubitemid 32435732)
21. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc Natl Acad Sci USA 98:5815-5820 (Pubitemid 32435725)
22. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95:6460-6464 (Pubitemid 28249035)
23. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283:29615-29619
24. Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, Gandy S (2005) Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med 2:e18
25. Cole SL, Grudzien A, Manhart IO, Kelly BL, Oakley H, Vassar R (2005) Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. J Biol Chem 280:18755-18770 (Pubitemid 41379577)
26. Ostrowski SM, Wilkinson BL, Golde TE, Landreth G (2007) Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem 282:26832-26844 (Pubitemid 47501902)
27. Zhou Y, Suram A, Venugopal C, Prakasam A, Lin S, Su Y, Li B, Paul SM, Sambamurti K (2008) Geranylgeranyl pyrophosphate stimulates gamma-secretase to increase the generation of Abeta and APP-CTFgamma. FASEB J 22:47-54
28. Hooff GP, Peters I, Wood WG, Muller WE, Eckert GP (2010) Modulation of cholesterol, farnesylpyrophosphate, and geranylgeranylpyrophosphate in neuroblastoma SH-SY5Y-APP695 cells: impact on amyloid beta-protein production. Mol Neurobiol 41:341-350
29. Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A (2006) Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl 185:63-70 (Pubitemid 44015227)
30. Li L, Cao D, Kim H, Lester R, Fukuchi K (2006) Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol 60:729-739 (Pubitemid 46061359)
31. Shinohara M, Sato N, Kurinami H, Takeuchi D, Takeda S, Shimamura M, Yamashita T, Uchiyama Y, Rakugi H, Morishita R (2010) Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance. J Biol Chem 285:22091-22102
32. Eikelenboom P, Veerhuis R, Exel EV, Hoozemans JJ, Rozemuller AJ, van Gool WA (2011) The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. Curr Alzheimer Res 8:142-150
33. Abraham CR, Selkoe DJ, Potter H (1988) Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52:487-501 (Pubitemid 18067514)
34. Bauer J, Strauss S, Schreiter-Gasser U, Ganter U, Schlegel P,Witt I, Yolk B, Berger M (1991) Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett 285:111-114
35. Coria F, Castano E, Prelli F, Larrondo-Lillo M, van Duinen S, Shelanski ML, Frangione B (1988) Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab Invest 58:454-458
36. Eikelenboom P, Stam FC (1982) Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol 57:239-242 (Pubitemid 12085182)
37. Cameron B, Landreth GE (2010) Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis 37:503-509
38. Fuller S, Steele M, Munch G (2010) Activated astroglia during chronic inflammation in Alzheimer's disease-do they neglect their neurosupportive roles? Mutat Res 690:40-49
39. Morgan K (2011) The three new pathways leading to Alzheimer's disease. Neuropathol Appl Neurobiol 37:353-357
40. Menge T, Hartung HP, Stuve O (2005) Statins-A cure-all for the brain? Nat Rev Neurosci 6:325-331
41. Sun YX, Crisby M, Lindgren S, Janciauskiene S (2003) Pravastatin inhibits pro-inflammatory effects of Alzheimer's peptide Abeta(1-42) in glioma cell culture in vitro. Pharmacol Res 47:119-126 (Pubitemid 36263446)
42. Wang H, Lynch JR, Song P, Yang HJ, Yates RB, Mace B, Warner DS, Guyton JR, Laskowitz DT (2007) Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol 206(1):59-69 (Pubitemid 46935123)
43. Townsend KP, Shytle DR, Bai Y, San N, Zeng J, Freeman M, Mori T, Fernandez F, Morgan D, Sanberg P, Tan J (2004) Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J Neurosci Res 78:167-176 (Pubitemid 39313788)
44. Pahan K, Sheikh FG, Namboodiri AM, Singh I (1997) Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 100:2671-2679 (Pubitemid 28007534)
45. Paintlia AS, Paintlia MK, Singh AK, Singh I (2008) Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol Pharmacol 73:1381-1393 (Pubitemid 351574828)
46. Lindberg C, Crisby M, Winblad B, Schultzberg M (2005) Effects of statins on microglia. J Neurosci Res 82:10-19 (Pubitemid 41604793)
47. Kou J, Kim HD, Jin J, Cao D, Li L, Lalonde R, Fukuchi K (2010) Simvastatin enhances immune responses to Abeta vaccination and attenuates vaccination-induced behavioral alterations. Brain Res 1356:102-111
48. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A, Landreth G (2005) Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 280:34202-34209 (Pubitemid 41443145)
49. Cordle A, Landreth G (2005) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. J Neurosci 25:299-307 (Pubitemid 40105600)
50. Franke C, NoldnerM, Abdel-Kader R, Johnson-Anuna LN, Gibson Wood W, Muller WE, Eckert GP (2007) Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiol Dis 25:438-445 (Pubitemid 46138047)
51. Johnson-Anuna LN, Eckert GP, Keller JH, Igbavboa U, Franke C, Fechner T, Schubert-Zsilavecz M, Karas M, Muller WE, Wood WG (2005) Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 312:786-793 (Pubitemid 40189580)
52. Famer D, Crisby M (2004) Rosuvastatin reduces caspase-3 activity and up-regulates alpha-secretase in human neuroblastoma SH-SY5Y cells exposed to A beta. Neurosci Lett 371:209-214 (Pubitemid 39440773)
53. Zacco A, Togo J, Spence K, Ellis A, Lloyd D, Furlong S, Piser T (2003) 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 23:11104-11111 (Pubitemid 37548945)
54. Bosel J, Gandor F, Harms C, Synowitz M, Harms U, Djoufack PC, Megow D, Dirnagl U, Hortnagl H, Fink KB, Endres M (2005) Neuroprotective effects of atorvastatin against glutamateinduced excitotoxicity in primary cortical neurones. J Neurochem 92:1386-1398 (Pubitemid 40389208)
55. Lapchak PA, Han MK (2010) Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator. Brain Res 1344:217-225
56. Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K (2009) Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci 29:13543-13556
57. Meske V, Albert F, Richter D, Schwarze J, Ohm TG (2003) Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. Eur J Neurosci 17:93-102 (Pubitemid 36098879)
58. Ramirez C, Tercero I, Pineda A, Burgos JS (2011) Simvastatin is the statin that most efficiently protects against kainate-induced excitotoxicity and memory impairment. J Alzheimers Dis 24:161-174
59. Salins P, Shawesh S, He Y, Dibrov A, Kashour T, Arthur G, Amara F (2007) Lovastatin protects human neurons against Abeta-induced toxicity and causes activation of beta-catenin-TCF/LEF signaling. Neurosci Lett 412:211-216 (Pubitemid 46109146)
60. Cespedes-Rubio A, Jurado FW, Cardona-Gomez GP (2010) p120 catenin/alphaN-catenin are molecular targets in the neuroprotection and neuronal plasticity mediated by atorvastatin after focal cerebral ischemia. J Neurosci Res 88:3621-3634
61. Kretz A, Schmeer C, Tausch S, Isenmann S (2006) Simvastatin promotes heat shock protein 27 expression and Akt activation in the rat retina and protects axotomized retinal ganglion cells in vivo. Neurobiol Dis 21:421-430 (Pubitemid 43099865)
62. Xu R, Chen J, Cong X, Hu S, Chen X (2008) Lovastatin protects mesenchymal stem cells against hypoxia- and serum deprivationinduced apoptosis by activation of PI3K/Akt and ERK1/2. J Cell Biochem 103:256-269
63. Rodriguez-Vita J, Sanchez-Galan E, Santamaria B, Sanchez- Lopez E, Rodrigues-Diez R, Blanco-Colio LM, Egido J, Ortiz A, Ruiz-Ortega M (2008) Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation. PLoS One 3:e3959
64. Balduini W, Mazzoni E, Carloni S, De Simoni MG, Perego C, Sironi L, Cimino M (2003) Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction, and does not affect endothelial nitric oxide synthase expression. Stroke 34:2007-2012 (Pubitemid 36944798)
65. Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, Zhang C, Lu M, Katakowski M, Feldkamp CS, ChoppM(2003) Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 53:743-751 (Pubitemid 36622511)
66. Lu D, Qu C, Goussev A, Jiang H, Lu C, Schallert T, Mahmood A, Chen J, Li Y, Chopp M (2007) Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma 24:1132-1146 (Pubitemid 47106287)
67. Wu H, Lu D, Jiang H, Xiong Y, Qu C, Li B, Mahmood A, Zhou D, Chopp M (2008) Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma 25:130-139 (Pubitemid 351252578)
68. Pooler AM, Xi SC, Wurtman RJ (2006) The 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor pravastatin enhances neurite outgrowth in hippocampal neurons. J Neurochem 97:716-723
69. Kannan M, Steinert JR, Forsythe ID, Smith AG, Chernova T (2010) Mevastatin accelerates loss of synaptic proteins and neurite degeneration in aging cortical neurons in a heme-independent manner. Neurobiol Aging 31:1543-1553
70. Schulz JG, Bosel J, Stoeckel M, Megow D, Dirnagl U, Endres M (2004) HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J Neurochem 89:24-32 (Pubitemid 38420671)
71. Vural K, Tuglu MI (2011) Neurotoxic effect of statins on mouse neuroblastoma NB2a cell line. Eur Rev Med Pharmacol Sci 15:985-991
72. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356:1627-1631
73. Wolozin B, KellmanW, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439-1443
74. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double- blind trial. Ann Neurol 52:346-350 (Pubitemid 35001502)
75. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C (2005) Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62:753-757 (Pubitemid 40656090)
76. Collins R, Armitage J, Parish S, Sleight P, Peto R (2002) MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebocontrolled trial. Lancet 360:7-22 (Pubitemid 34756487)
77. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360:1623-1630 (Pubitemid 35379733)
78. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM (2003) Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 23:871-880 (Pubitemid 36875671)
79. Shepardson NE, Shankar GM, Selkoe DJ (2010) Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol 68:1239-1244
80. Douma TN, Borre Y, Hendriksen H, Olivier B, Oosting RS (2011) Simvastatin improves learning and memory in control but not in olfactory bulbectomized rats. Psychopharmacology (Berl) 216:537-544
81. McGaugh JL (2000)Memory - a century of consolidation. Science 287:248-251 (Pubitemid 30046744)
82. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298:789-791 (Pubitemid 35231524)
83. Clarke RM, O'Connell F, Lyons A, Lynch MA (2007) The HMGCoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta1-42 in the rat hippocampus in vivo. Neuropharmacology 52:136-145 (Pubitemid 46026837)
84. Kotti TJ, Ramirez DM, Pfeiffer BE, Huber KM, Russell DW (2006) Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc Natl Acad Sci USA 103:3869-3874 (Pubitemid 43376647)
85. Kotti T, Head DD, McKenna CE, Russell DW (2008) Biphasic requirement for geranylgeraniol in hippocampal long-term potentiation. Proc Natl Acad Sci USA 105:11394-11399
86. Mans RA, Chowdhury N, Cao D, McMahon LL, Li L (2010) Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice. Neuroscience 166:435-444
87. Mans RA, McMahon LL, Li L (2011) Simvastatin-mediated enhancement of long-term potentiation is driven by farnesylpyrophosphate depletion and inhibition of farnesylation. Neuroscience. doi:10.1016/j.neuroscience.2011.12. 007
88. Horwood JM, Dufour F, Laroche S, Davis S (2006) Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. Eur J Neurosci 23:3375-3384
89. LiW, Cui Y, Kushner SA, Brown RA, Jentsch JD, Frankland PW, Cannon TD, Silva AJ (2005) The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mousemodel of neurofibromatosis type 1. Curr Biol 15:1961-1967 (Pubitemid 41566145)
90. Thornton C, Yaka R, Dinh S, Ron D (2003) H-Ras modulates Nmethyl- D-aspartate receptor function via inhibition of Src tyrosine kinase activity. J Biol Chem 278:23823-23829 (Pubitemid 36830207)
91. Yaka R, Thornton C, Vagts AJ, Phamluong K, Bonci A, Ron D (2002) NMDA receptor function is regulated by the inhibitory scaffolding protein, RACK1. Proc Natl Acad Sci USA 99:5710-5715 (Pubitemid 34411615)
92. Manabe T, Aiba A, Yamada A, Ichise T, Sakagami H, Kondo H, Katsuki M (2000) Regulation of long-term potentiation by H-Ras through NMDA receptor phosphorylation. J Neurosci 20:2504-2511 (Pubitemid 30220337)
93. Eckert GP, Hooff GP, Strandjord DM, Igbavboa U, Volmer DA, Muller WE, Wood WG (2009) Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiol Dis 35:251-257
94. Fleisch H, Russell RG, Straumann F (1966) Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212:901-903
95. Fleisch H, Russell RG, Francis MD (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262-1264
96. Fleisch H, Russell RG, Simpson B, Muhlbauer RC (1969) Prevention by a diphosphonate of immobilization "osteoporosis" in rats. Nature 223:211-212
97. Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49:2-19
98. Rogers MJ, Crockett JC, Coxon FP, Monkkonen J (2011) Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49:34-41
99. Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP (2010) Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 16:2950-2960
100. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133-138 (Pubitemid 29036065)
101. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467-1476 (Pubitemid 30484516)
102. Clezardin P, Ebetino FH, Fournier PG (2005) Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 65:4971-4974 (Pubitemid 40827299)
103. Dechat T, Shimi T, Adam SA, Rusinol AE, Andres DA, Spielmann HP, Sinensky MS, Goldman RD (2007) Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging. Proc Natl Acad Sci USA 104:4955-4960 (Pubitemid 47186158)
104. Young SG, Meta M, Yang SH, Fong LG (2006) Prelamin A farnesylation and progeroid syndromes. J Biol Chem 281:39741-39745 (Pubitemid 46041777)
105. Varela I, Pereira S, Ugalde AP, Navarro CL, Suarez MF, Cau P, Cadinanos J, Osorio FG, Foray N, Cobo J, de Carlos F, Levy N, Freije JM, Lopez-Otin C (2008) Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med 14:767-772
106. Fawcett JR, Bordayo EZ, Jackson K, Liu H, Peterson J, Svitak A, Frey WH 2nd (2002) Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer's brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants. Brain Res 950:10-20 (Pubitemid 35253912)
107. Cibickova L, Palicka V, Cibicek N, Cermakova E, Micuda S, Bartosova L, Jun D (2007) Differential effects of statins and alendronate on cholinesterases in serum and brain of rats. Physiol Res 56:765-770
108. Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RG, Oppermann U (2006) The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 103:7829-7834
109. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ (1998) Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13:1668-1678 (Pubitemid 28491995)
110. Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W (2006) Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 1:267-273 (Pubitemid 43700307)
111. Jahnke W, Rondeau JM, Cotesta S, Marzinzik A, Pelle X, Geiser M, Strauss A, Gotte M, Bitsch F, Hemmig R, Henry C, Lehmann S, Glickman JF, Roddy TP, Stout SJ, Green JR (2010) Allosteric non-bisphosphonate FPPS inhibitors identified by fragmentbased discovery. Nat Chem Biol 6:660-666
112. Leung KF, Baron R, Seabra MC (2006) Thematic review series: lipid posttranslational modifications. geranylgeranylation of Rab GTPases. J Lipid Res 47:467-475
113. Berndt N, Hamilton AD, Sebti SM (2011) Targeting protein prenylation for cancer therapy. Nat Rev Cancer 11:775-791
114. Tsimberidou AM, Chandhasin C, Kurzrock R (2010) Farnesyltransferase inhibitors: where are we now? Expert Opin Investig Drugs 19:1569-1580
115. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260:1934-1937 (Pubitemid 23258273)
116. Liu M, Sjogren AK, Karlsson C, Ibrahim MX, Andersson KM, Olofsson FJ, Wahlstrom AM, Dalin M, Yu H, Chen Z, Yang SH, Young SG, Bergo MO (2010) Targeting the protein prenyltransferases efficiently reduces tumor development in mice with KRAS-induced lung cancer. Proc Natl Acad Sci USA 107:6471-6476
117. Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM (2001) The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem 276:16161-16167
118. Crespo NC, Delarue F, Ohkanda J, Carrico D, Hamilton AD, Sebti SM (2002) The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death Differ 9:702-709 (Pubitemid 34778036)
119. Barrington RE, Subler MA, Rands E, Omer CA, Miller PJ, Hundley JE, Koester SK, Troyer DA, Bearss DJ, Conner MW, Gibbs JB, Hamilton K, Koblan KS, Mosser SD, O'Neill TJ, Schaber MD, Senderak ET, Windle JJ, Oliff A, Kohl NE (1998) A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 18:85-92 (Pubitemid 28021020)
120. Zhang B, Prendergast GC, Fenton RG (2002) Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res 62:450-458 (Pubitemid 34106418)
121. Reuveni H, Klein S, Levitzki A (2003) The inhibition of Ras farnesylation leads to an increase in p27Kip1 and G1 cell cycle arrest. Eur J Biochem 270:2759-2772 (Pubitemid 36805616)
122. Cohen-Jonathan E, Evans SM, Koch CJ, Muschel RJ, McKenna WG, Wu J, Bernhard EJ (2001) The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res 61:2289-2293 (Pubitemid 32692061)
123. Kim CK, Choi YK, Lee H, Ha KS, Won MH, Kwon YG, Kim YM (2010) The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signal pathways.Mol Pharmacol 78:142-150
124. Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM (1997) Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 15:1283-1288 (Pubitemid 27429743)
125. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM (1997) Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 272:14093-14097 (Pubitemid 27232813)
126. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai JK (1997) K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272:14459-14464 (Pubitemid 27232866)
127. Mehta IS, Bridger JM, Kill IR (2010) Progeria, the nucleolus and farnesyltransferase inhibitors. Biochem Soc Trans 38:287-291
128. Fong LG, Frost D, Meta M, Qiao X, Yang SH, Coffinier C, Young SG (2006) A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 311:1621-1623
129. Yang SH, Meta M, Qiao X, Frost D, Bauch J, Coffinier C, Majumdar S, Bergo MO, Young SG, Fong LG (2006) A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest 116:2115-2121 (Pubitemid 44162320)
130. Capell BC, Olive M, Erdos MR, Cao K, Faddah DA, Tavarez UL, Conneely KN, Qu X, San H, Ganesh SK, Chen X, Avallone H, Kolodgie FD, Virmani R, Nabel EG, Collins FS (2008) A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci USA 105:15902-15907
131. Kieran MW, Gordon L, Kleinman M (2007) New approaches to progeria. Pediatrics 120:834-841 (Pubitemid 47549572)
132. Work LM, McPhaden AR, Pyne NJ, Pyne S, Wadsworth RM, Wainwright CL (2001) Short-term local delivery of an inhibitor of Ras farnesyltransferase prevents neointima formation in vivo after porcine coronary balloon angioplasty. Circulation 104:1538-1543 (Pubitemid 32917348)
133. Eastman RT, Buckner FS, Yokoyama K, Gelb MH, Van Voorhis WC (2006) Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J Lipid Res 47:233-240
134. Carrico D, Ohkanda J, Kendrick H, Yokoyama K, Blaskovich MA, Bucher CJ, Buckner FS, Van Voorhis WC, Chakrabarti D, Croft SL, Gelb MH, Sebti SM, Hamilton AD (2004) In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorg Med Chem 12:6517-6526 (Pubitemid 39535174)
135. Nallan L, Bauer KD, Bendale P, Rivas K, Yokoyama K, Horney CP, Pendyala PR, Floyd D, Lombardo LJ, Williams DK, Hamilton A, Sebti S, Windsor WT, Weber PC, Buckner FS, Chakrabarti D, Gelb MH, Van Voorhis WC (2005) Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem 48:3704-3713 (Pubitemid 40776846)
136. Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, Ohashi K, Meuse L, Kay MA, Casey JL, Sebti SM, Hamilton AD, Glenn JS (2003) In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 112:407-414 (Pubitemid 38063769)
137. Ye X, Carew TJ (2010) Small G protein signaling in neuronal plasticity and memory formation: the specific role of ras family proteins. Neuron 68:340-361
138. Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, Ohno M, Kucherlapati
139. Liu Z, Meray RK, Grammatopoulos TN, Fredenburg RA, Cookson MR, Liu Y, Logan T, Lansbury PT Jr (2009) Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc Natl Acad Sci USA 106:4635-4640
140. O'Dwyer PJ, Gallagher M, Nguyen B, Waddell MJ, Chiorean EG (2010) Phase I accelerated dose-escalating safety and pharmacokinetic (PK) study of GGTI-2418, a novel geranylgeranyltransferase I inhibitor in patients with refractory solid tumors. Ann Oncol 21:ii42
141. Finder JD, Litz JL, Blaskovich MA, McGuire TF, Qian Y, Hamilton AD, Davies P, Sebti SM (1997) Inhibition of protein geranylgeranylation causes a superinduction of nitric-oxide synthase-2 by interleukin-1beta in vascular smooth muscle cells. J Biol Chem 272:13484-13488 (Pubitemid 27224775)
142. Zuckerbraun BS, Barbato JE, Hamilton A, Sebti S, Tzeng E (2005) Inhibition of geranylgeranyltransferase I decreases generation of vascular reactive oxygen species and increases vascular nitric oxide production. J Surg Res 124:256-263 (Pubitemid 40463726)
143. Holmberg E, Nordstrom T, Gross M, Kluge B, Zhang SX, Doolen S (2006) Simvastatin promotes neurite outgrowth in the presence of inhibitory molecules found in central nervous system injury. J Neurotrauma 23:1366-1378 (Pubitemid 46489622)
144. Reid TS, Terry KL, Casey PJ, Beese LS (2004) Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol 343:417-433 (Pubitemid 39296875)
145. Govek EE, Hatten ME, Van Aelst L (2011) The role of Rho GTPase proteins in CNS neuronal migration. Dev Neurobiol 71:528-553
146. Tolias KF, Duman JG, Um K (2011) Control of synapse development and plasticity by Rho GTPase regulatory proteins. Prog Neurobiol 94:133-148
147. Newey SE, Velamoor V, Govek EE, Van Aelst L (2005) Rho GTPases, dendritic structure, and mental retardation. J Neurobiol 64:58-74 (Pubitemid 40847431)
148. Perez-Sala D (2007) Protein isoprenylation in biology and disease: general overview and perspectives from studies with genetically engineered animals. Front Biosci 12:4456-4472
149. Maurer-Stroh S, Koranda M, Benetka W, Schneider G, Sirota FL, Eisenhaber F (2007) Towards complete sets of farnesylated and geranylgeranylated proteins. PLoS Comput Biol 3:e66
150. Chan LN, Hart C, Guo L, Nyberg T, Davies BS, Fong LG, Young SG, Agnew BJ, Tamanoi F (2009) A novel approach to tag and identify geranylgeranylated proteins. Electrophoresis 30:3598-3606
151. DeGraw AJ, Palsuledesai C, Ochocki JD, Dozier JK, Lenevich S, Rashidian M, Distefano MD (2010) Evaluation of alkynemodified isoprenoids as chemical reporters of protein prenylation. Chem Biol Drug Des 76:460-471
152. Kho Y, Kim SC, Jiang C, Barma D, Kwon SW, Cheng J, Jaunbergs J, Weinbaum C, Tamanoi F, Falck J, Zhao Y (2004) A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proc Natl Acad Sci USA 101:12479-12484 (Pubitemid 39122049)
153. Nguyen UT, Guo Z, Delon C, Wu Y, Deraeve C, Franzel B, Bon RS, Blankenfeldt W, Goody RS, Waldmann H, Wolters D, Alexandrov K (2009) Analysis of the eukaryotic prenylome by isoprenoid affinity tagging. Nat Chem Biol 5:227-235
154. Onono FO, Morgan MA, Spielmann HP, Andres DA, Subramanian T, Ganser A, Reuter CW (2010) A tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blotting. Mol Cell Proteomics 9:742-751
155. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogencontaining bisphosphonates. J Pharmacol Exp Ther 296:235-242 (Pubitemid 32112446)
156. Leu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA (2006) Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 38:628-636
157. Cremers S, Papapoulos S (2011) Pharmacology of bisphosphonates. Bone 49:42-49
158. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G (1998) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 83:683-690 (Pubitemid 28462781)
159. Lin CH, Yeh SH, Lu KT, Leu TH, Chang WC, Gean PW (2001) A role for the PI-3 kinase signaling pathway in fear conditioning and synaptic plasticity in the amygdala. Neuron 31:841-851
160. Magrane J, Rosen KM, Smith RC, Walsh K, Gouras GK, Querfurth HW (2005) Intraneuronal beta-amyloid expression downregulates the Akt survival pathway and blunts the stress response. J Neurosci 25:10960-10969 (Pubitemid 41692626)
161. O'Dell TJ, Huang PL, Dawson TM, Dinerman JL, Snyder SH, Kandel ER, Fishman MC (1994) Endothelial NOS and the blockade of LTP by NOS inhibitors in mice lacking neuronal NOS. Science 265:542-546 (Pubitemid 24265004)
162. Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S, Teng KK, Yung WH, Hempstead BL, Lu B (2004) Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 306:487-491 (Pubitemid 39372449)
163. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P (2005) Regulation of NMDA receptor trafficking by amyloidbeta. Nat Neurosci 8:1051-1058 (Pubitemid 41061516)
164. Sweatt JD (2004) Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 14:311-317 (Pubitemid 38759861)